Abozaid Ghada Mohammed, Al-Omar Hussain Abdulrahman, Alrabiah Abdulaziz, Alomary Hiba, McKnight Amy Jayne
Centre for Public Health, Institute of Clinical Sciences B, Royal Victoria Hospital, Dentistry and Biomedical Sciences, Queen's University Belfast School of Medicine, Belfast, United Kingdom.
Pharmacy Practice Department, College of Pharmacy, Princess Nourah Bint Abdulrahman University, Riyadh, Saudi Arabia.
Front Pharmacol. 2025 Jul 17;16:1595967. doi: 10.3389/fphar.2025.1595967. eCollection 2025.
Rare diseases are characterized by low prevalence, a profound impact on patients, and significant challenges in accessing treatment. In Saudi Arabia, the absence of an official definition hampers policymaking, resource allocation, and orphan drugs accessibility. This study aimed to address this gap by proposing a definition of rare diseases using inputs and views from a Saudi multi-stakeholder workshop.
A 1-day workshop was hosted in collaboration with the Saudi Health Council in Riyadh on 5 June 2023, involving 59 participants from various sectors, including clinicians, policymakers, patient advocates, and industry professionals. Using the Vevox platform, participants engaged in structured activities comprising a demographic survey and 10 interactive voting sessions. Preferred qualitative and quantitative criteria for defining rare diseases were identified and analyzed using descriptive statistics and thematic and content analysis of open-ended questions.
The findings indicated a strong preference (96%) for an integrated definition combining qualitative and quantitative criteria. Key qualitative terms such as "Disease" (62%), "Serious" (53%), and "Disorder" (51%) were favored for their clarity and broad applicability. "Genetic" etiology was preferred by 91% of participants, citing its relevance and data availability. Patient-centered criteria, including "life-threatening" (73%) and "considerable reduction in quality of life" (91%), were emphasized. Economic and resource-focused considerations, such as "Lack of Resources" and "Combined Efforts to Prevent" (each at 60%), reflected key unmet needs in the current healthcare landscape. Among quantitative criteria, "Prevalence" (82%) emerged as the most accepted, aligned with international practices, although opinions were mixed on the inclusion of population size thresholds, underscoring the definitional complexity of defining RDs with both precision and flexibility.
This study provides a foundational basis and scientific root for defining rare diseases in the Saudi context, addressing key gaps in healthcare policies. By integrating evidence-based, patient-centered, and resource-oriented criteria, the proposed definition supports equitable access, improved patient care, and sustainable innovation, in alignment with Saudi Arabia's Vision 2030 goals. Further refinement with broader stakeholder inputs is essential for the successful integration of Saudi healthcare policies.
罕见病的特点是患病率低、对患者影响深远,且在获得治疗方面面临重大挑战。在沙特阿拉伯,缺乏官方定义阻碍了政策制定、资源分配以及孤儿药的可及性。本研究旨在通过利用沙特多利益相关方研讨会的意见和观点提出罕见病定义来填补这一空白。
2023年6月5日,与沙特卫生委员会合作在利雅得举办了为期一天的研讨会,有59名来自不同部门的参与者,包括临床医生、政策制定者、患者权益倡导者和行业专业人士。使用Vevox平台,参与者参与了结构化活动,包括人口统计学调查和10次互动投票环节。使用描述性统计以及对开放式问题的主题和内容分析,确定并分析了定义罕见病的首选定性和定量标准。
研究结果表明,强烈倾向于(96%)采用结合定性和定量标准的综合定义。关键的定性术语,如“疾病”(62%)、“严重”(53%)和“病症”(51%),因其清晰度和广泛适用性而受到青睐。91%的参与者倾向于“遗传”病因,理由是其相关性和数据可得性。强调了以患者为中心的标准,包括“危及生命”(73%)和“生活质量大幅下降”(91%)。以经济和资源为重点的考量因素,如“资源匮乏”和“联合预防努力”(各占60%),反映了当前医疗格局中未得到满足的关键需求。在定量标准中,“患病率”(82%)成为最被接受的标准,这与国际惯例一致,尽管对于是否纳入人口规模阈值存在不同意见,这凸显了精确且灵活地定义罕见病的定义复杂性。
本研究为在沙特背景下定义罕见病提供了基础依据和科学根源,填补了医疗政策中的关键空白。通过整合基于证据、以患者为中心和以资源为导向的标准,所提出的定义支持公平可及性、改善患者护理以及可持续创新,符合沙特阿拉伯的2030年愿景目标。通过更广泛的利益相关方投入进行进一步完善对于沙特医疗政策的成功整合至关重要。